PRTK · Paratek Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $160.27M | $130.16M | $46.92M | $16.54M | $12.62M | $12.62M |
| Cost of Revenue | $23.06M | $21.54M | $8.65M | $3.48M | - | - |
| Gross Profit | $137.21M | $108.63M | $38.27M | $13.06M | - | - |
| R&D | $37.82M | $30.35M | $23.92M | $39.55M | $57.51M | $60.07M |
| SG&A | $145.60M | $119.40M | $89.86M | $63.66M | $63.66M | $36.97M |
| Total Operating Expenses | $206.48M | $171.29M | $122.43M | $132.17M | $121.20M | $97.20M |
| D&A | - | - | - | - | - | $1.27M |
| Operating Income | ($46.21M) | ($41.13M) | ($75.50M) | ($115.63M) | ($104.08M) | ($84.58M) |
| Interest Expense | $18.12M | $17.41M | $20.24M | $16.40M | $10.98M | $5.08M |
| Income Tax | $57.0K | $600.0K | - | $301.0K | $502.0K | $753.0K |
| Net Income | ($63.57M) | ($59.08M) | ($96.54M) | ($128.79M) | ($112.36M) | ($89.07M) |
| EPS - Basic | ($1.22) | - | - | - | - | - |
| EPS - Diluted | ($1.22) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $34.25M | $80.37M | $105.16M | $102.30M | $46.99M | $35.42M |
| Accounts Receivable | $74.66M | $29.44M | $11.88M | $8.47M | $41.0K | $5.04M |
| Inventory | $16.57M | $11.02M | $14.55M | $11.58M | - | - |
| Accounts Payable | $5.31M | $5.39M | $1.81M | $4.12M | $2.09M | $3.56M |
| Current Assets | $136.84M | $152.10M | $164.12M | $243.35M | $255.24M | $160.49M |
| Total Assets | $172.54M | $183.87M | $176.85M | $251.08M | $300.19M | $163.70M |
| Current Liabilities | $37.39M | $31.30M | $23.95M | $24.20M | $17.71M | $16.79M |
| Long-term Debt | $256.95M | $254.43M | $250.47M | $260.73M | $228.96M | $59.19M |
| Total Liabilities | $343.58M | $311.66M | $279.11M | $290.73M | $252.61M | $81.22M |
| Stockholders' Equity | ($171.04M) | ($127.79M) | ($102.26M) | ($39.65M) | $47.58M | $82.48M |
| Retained Earnings | ($930.45M) | ($866.88M) | ($807.80M) | ($711.26M) | ($582.47M) | ($470.11M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($66.14M) | ($48.27M) | ($103.42M) | ($134.04M) | ($78.57M) | ($78.57M) |
| Investing Cash Flow | $14.80M | $4.51M | $92.50M | $134.55M | ($42.66M) | ($42.00M) |
| Financing Cash Flow | $5.09M | $18.33M | $11.34M | $57.62M | $103.03M | $103.03M |
| CapEx | $36.0K | $373.0K | $376.0K | $239.0K | $60.0K | $690.0K |
| Free Cash Flow | ($66.18M) | ($48.65M) | ($103.80M) | ($134.28M) | ($78.63M) | ($79.26M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 85.6% | 83.5% | 81.6% | 78.9% | - | - |
| Operating margin | -28.8% | -31.6% | -160.9% | -698.9% | -825.0% | -670.4% |
| EBITDA margin | - | - | - | - | - | -660.4% |
| Net margin | -39.7% | -45.4% | -205.7% | -778.5% | -890.6% | -706.0% |
| Free cash flow margin | -41.3% | -37.4% | -221.2% | -811.7% | -623.3% | -628.3% |
| FCF / Net income | 1.04 | 0.82 | 1.08 | 1.04 | 0.70 | 0.89 |
| R&D / Revenue | 23.6% | 23.3% | 51.0% | 239.1% | 455.8% | 476.2% |
| SG&A / Revenue | 90.8% | 91.7% | 191.5% | 384.8% | 504.6% | 293.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -36.8% | -32.1% | -54.6% | -51.3% | -37.4% | -54.4% |
| Return on equity | 37.2% | 46.2% | 94.4% | 324.8% | -236.2% | -108.0% |
| Return on invested capital | -42.5% | -25.7% | - | -41.3% | -29.7% | -47.2% |
| Liquidity | ||||||
| Current ratio | 3.66 | 4.86 | 6.85 | 10.06 | 14.41 | 9.56 |
| Quick ratio | 3.22 | 4.51 | 6.24 | 9.58 | 14.41 | 9.56 |
| Cash ratio | 0.92 | 2.57 | 4.39 | 4.23 | 2.65 | 2.11 |
| Leverage | ||||||
| Debt / Equity | -1.50 | -1.99 | -2.45 | -6.58 | 4.81 | 0.72 |
| Debt / Assets | 1.49 | 1.38 | 1.42 | 1.04 | 0.76 | 0.36 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -2.6x | -2.4x | -3.7x | -7.0x | -9.5x | -16.7x |
| Equity multiplier | -1.01 | -1.44 | -1.73 | -6.33 | 6.31 | 1.98 |
| Liabilities / Assets | 1.99 | 1.69 | 1.58 | 1.16 | 0.84 | 0.50 |
| Efficiency | ||||||
| Asset turnover | 0.93 | 0.71 | 0.27 | 0.07 | 0.04 | 0.08 |
| Inventory turnover | 1.39 | 1.95 | 0.59 | 0.30 | - | - |
| Days sales outstanding | 170d | 83d | 92d | 187d | 1d | 146d |
| Days inventory outstanding | 262d | 187d | 614d | 1213d | - | - |
| Days payable outstanding | 84d | 91d | 76d | 431d | - | - |
| Cash conversion cycle | 348d | 178d | 630d | 969d | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 23.1% | 177.4% | 183.6% | 31.1% | 0.0% | 43403.4% |
| Revenue CAGR (3y) | 113.2% | 117.7% | 54.9% | 729.4% | - | - |
| Revenue CAGR (5y) | 66.3% | 437.5% | - | - | - | 5.6% |
| Gross profit growth (YoY) | 26.3% | 183.8% | 193.1% | - | - | - |
| Operating income growth (YoY) | -12.3% | 45.5% | 34.7% | -11.1% | -23.1% | 22.7% |
| Net income growth (YoY) | -7.6% | 38.8% | 25.0% | -14.6% | -26.1% | 20.2% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -36.0% | 53.1% | 22.7% | -70.8% | 0.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -33.8% | -25.0% | -157.9% | - | -42.3% | 15.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$130.16M totalProduct$106.08M · 81.5%
Government Contract Grant Revenue$9.21M · 7.1%
Collaboration And Royalty Revenue$8.23M · 6.3%
Government Contract Service Revenue$6.64M · 5.1%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-4.27
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Paratek Pharmaceuticals against the 5 most active filers in the same SIC group.